133 related articles for article (PubMed ID: 34577783)
21. Hybrid selection of transcribed sequences from microdissected DNA: isolation of genes within amplified region at 20q11-q13.2 in breast cancer.
Guan XY; Xu J; Anzick SL; Zhang H; Trent JM; Meltzer PS
Cancer Res; 1996 Aug; 56(15):3446-50. PubMed ID: 8758910
[TBL] [Abstract][Full Text] [Related]
22. Identification of copy number gain and overexpressed genes on chromosome arm 20q by an integrative genomic approach in cervical cancer: potential role in progression.
Scotto L; Narayan G; Nandula SV; Arias-Pulido H; Subramaniyam S; Schneider A; Kaufmann AM; Wright JD; Pothuri B; Mansukhani M; Murty VV
Genes Chromosomes Cancer; 2008 Sep; 47(9):755-65. PubMed ID: 18506748
[TBL] [Abstract][Full Text] [Related]
23. Genomic analysis and selective small molecule inhibition identifies BCL-X(L) as a critical survival factor in a subset of colorectal cancer.
Zhang H; Xue J; Hessler P; Tahir SK; Chen J; Jin S; Souers AJ; Leverson JD; Lam LT
Mol Cancer; 2015 Jul; 14():126. PubMed ID: 26134786
[TBL] [Abstract][Full Text] [Related]
24. Significance of FGF9 gene in resistance to anti-EGFR therapies targeting colorectal cancer: A subset of colorectal cancer patients with FGF9 upregulation may be resistant to anti-EGFR therapies.
Mizukami T; Togashi Y; Naruki S; Banno E; Terashima M; de Velasco MA; Sakai K; Yoneshige A; Hayashi H; Fujita Y; Tomida S; Nakajima TE; Fujino T; Boku N; Ito A; Nakagawa K; Nishio K
Mol Carcinog; 2017 Jan; 56(1):106-117. PubMed ID: 26916220
[TBL] [Abstract][Full Text] [Related]
25. BCL-XL mediates the strong selective advantage of a 20q11.21 amplification commonly found in human embryonic stem cell cultures.
Avery S; Hirst AJ; Baker D; Lim CY; Alagaratnam S; Skotheim RI; Lothe RA; Pera MF; Colman A; Robson P; Andrews PW; Knowles BB
Stem Cell Reports; 2013; 1(5):379-86. PubMed ID: 24286026
[TBL] [Abstract][Full Text] [Related]
26. IRS2 copy number gain, KRAS and BRAF mutation status as predictive biomarkers for response to the IGF-1R/IR inhibitor BMS-754807 in colorectal cancer cell lines.
Huang F; Chang H; Greer A; Hillerman S; Reeves KA; Hurlburt W; Cogswell J; Patel D; Qi Z; Fairchild C; Ryseck RP; Wong TW; Finckenstein FG; Jackson J; Carboni JM
Mol Cancer Ther; 2015 Feb; 14(2):620-30. PubMed ID: 25527633
[TBL] [Abstract][Full Text] [Related]
27. Mitotic checkpoint regulator RAE1 promotes tumor growth in colorectal cancer.
Kobayashi Y; Masuda T; Fujii A; Shimizu D; Sato K; Kitagawa A; Tobo T; Ozato Y; Saito H; Kuramitsu S; Noda M; Otsu H; Mizushima T; Doki Y; Eguchi H; Mori M; Mimori K
Cancer Sci; 2021 Aug; 112(8):3173-3189. PubMed ID: 34008277
[TBL] [Abstract][Full Text] [Related]
28. Analysis of Cancer Genomic Amplifications Identifies Druggable Collateral Dependencies within the Amplicon.
Pons G; Gallo-Oller G; Navarro N; Zarzosa P; Sansa-Girona J; García-Gilabert L; Magdaleno A; Segura MF; Sánchez de Toledo J; Gallego S; Moreno L; Roma J
Cancers (Basel); 2023 Mar; 15(6):. PubMed ID: 36980521
[TBL] [Abstract][Full Text] [Related]
29. Molecular Landscape of Acquired Resistance to Targeted Therapy Combinations in BRAF-Mutant Colorectal Cancer.
Oddo D; Sennott EM; Barault L; Valtorta E; Arena S; Cassingena A; Filiciotto G; Marzolla G; Elez E; van Geel RM; Bartolini A; Crisafulli G; Boscaro V; Godfrey JT; Buscarino M; Cancelliere C; Linnebacher M; Corti G; Truini M; Siravegna G; Grasselli J; Gallicchio M; Bernards R; Schellens JH; Tabernero J; Engelman JA; Sartore-Bianchi A; Bardelli A; Siena S; Corcoran RB; Di Nicolantonio F
Cancer Res; 2016 Aug; 76(15):4504-15. PubMed ID: 27312529
[TBL] [Abstract][Full Text] [Related]
30. Chromosomal imbalance maps of human 5FU-resistant colorectal cancer cell lines: implications in the analysis of 5FU-acquired resistance mechanisms.
Plasencia C; Rooney PH; Taron M; Martinez-Balibrea E; McLeod HL; Abad A
Int J Oncol; 2003 May; 22(5):945-53. PubMed ID: 12684658
[TBL] [Abstract][Full Text] [Related]
31. 8p11.23 Amplification in Breast Cancer: Molecular Characteristics, Prognosis and Targeted Therapy.
Voutsadakis IA
J Clin Med; 2020 Sep; 9(10):. PubMed ID: 32987805
[TBL] [Abstract][Full Text] [Related]
32. RING-Finger Protein 6 Amplification Activates JAK/STAT3 Pathway by Modifying SHP-1 Ubiquitylation and Associates with Poor Outcome in Colorectal Cancer.
Liang Q; Ma D; Zhu X; Wang Z; Sun TT; Shen C; Yan T; Tian X; Yu T; Guo F; Tang J; Lin Y; Chen H; Zhou C; Ge Z; Zhong M; Chen J; Liu Q; Wang Z; Fang JY; Chen H; Hong J
Clin Cancer Res; 2018 Mar; 24(6):1473-1485. PubMed ID: 29288235
[No Abstract] [Full Text] [Related]
33. Triple-negative breast cancers with amplification of JAK2 at the 9p24 locus demonstrate JAK2-specific dependence.
Balko JM; Schwarz LJ; Luo N; Estrada MV; Giltnane JM; Dávila-González D; Wang K; Sánchez V; Dean PT; Combs SE; Hicks D; Pinto JA; Landis MD; Doimi FD; Yelensky R; Miller VA; Stephens PJ; Rimm DL; Gómez H; Chang JC; Sanders ME; Cook RS; Arteaga CL
Sci Transl Med; 2016 Apr; 8(334):334ra53. PubMed ID: 27075627
[TBL] [Abstract][Full Text] [Related]
34. Tankyrase Inhibition Blocks Wnt/β-Catenin Pathway and Reverts Resistance to PI3K and AKT Inhibitors in the Treatment of Colorectal Cancer.
Arqués O; Chicote I; Puig I; Tenbaum SP; Argilés G; Dienstmann R; Fernández N; Caratù G; Matito J; Silberschmidt D; Rodon J; Landolfi S; Prat A; Espín E; Charco R; Nuciforo P; Vivancos A; Shao W; Tabernero J; Palmer HG
Clin Cancer Res; 2016 Feb; 22(3):644-56. PubMed ID: 26224873
[TBL] [Abstract][Full Text] [Related]
35. Integrated analysis of whole genome exon array and array-comparative genomic hybridization in gastric and colorectal cancer cells.
Furuta K; Arao T; Sakai K; Kimura H; Nagai T; Tamura D; Aomatsu K; Kudo K; Kaneda H; Fujita Y; Matsumoto K; Yamada Y; Yanagihara K; Sekijima M; Nishio K
Cancer Sci; 2012 Feb; 103(2):221-7. PubMed ID: 22034905
[TBL] [Abstract][Full Text] [Related]
36. Chromosomal amplification is associated with cisplatin resistance of human male germ cell tumors.
Rao PH; Houldsworth J; Palanisamy N; Murty VV; Reuter VE; Motzer RJ; Bosl GJ; Chaganti RS
Cancer Res; 1998 Oct; 58(19):4260-3. PubMed ID: 9766648
[TBL] [Abstract][Full Text] [Related]
37. The genomic landscape of response to EGFR blockade in colorectal cancer.
Bertotti A; Papp E; Jones S; Adleff V; Anagnostou V; Lupo B; Sausen M; Phallen J; Hruban CA; Tokheim C; Niknafs N; Nesselbush M; Lytle K; Sassi F; Cottino F; Migliardi G; Zanella ER; Ribero D; Russolillo N; Mellano A; Muratore A; Paraluppi G; Salizzoni M; Marsoni S; Kragh M; Lantto J; Cassingena A; Li QK; Karchin R; Scharpf R; Sartore-Bianchi A; Siena S; Diaz LA; Trusolino L; Velculescu VE
Nature; 2015 Oct; 526(7572):263-7. PubMed ID: 26416732
[TBL] [Abstract][Full Text] [Related]
38. PLAGL2 and POFUT1 are regulated by an evolutionarily conserved bidirectional promoter and are collaboratively involved in colorectal cancer by maintaining stemness.
Li D; Lin C; Li N; Du Y; Yang C; Bai Y; Feng Z; Su C; Wu R; Song S; Yan P; Chen M; Jain A; Huang L; Zhang Y; Li X
EBioMedicine; 2019 Jul; 45():124-138. PubMed ID: 31279780
[TBL] [Abstract][Full Text] [Related]
39. FGFR2 amplification is predictive of sensitivity to regorafenib in gastric and colorectal cancers in vitro.
Cha Y; Kim HP; Lim Y; Han SW; Song SH; Kim TY
Mol Oncol; 2018 Jun; 12(7):993-1003. PubMed ID: 29573334
[TBL] [Abstract][Full Text] [Related]
40. Mechanisms of Primary Drug Resistance in
Malchers F; Ercanoglu M; Schütte D; Castiglione R; Tischler V; Michels S; Dahmen I; Brägelmann J; Menon R; Heuckmann JM; George J; Ansén S; Sos ML; Soltermann A; Peifer M; Wolf J; Büttner R; Thomas RK
Clin Cancer Res; 2017 Sep; 23(18):5527-5536. PubMed ID: 28630215
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
